The new SPAC intends to focus its search on targets in the healthcare industry with an enterprise value of approximately $500 million to $1 billion. Deep Medicine is led by CEO and Chairman of the Board Humphrey P. Polanen and CFO Weixuan Luo.
Total SPAC deal count for 2021 year-to-date is now 492. This offering is expected to close on Friday, October 29.
I-Bankers Securities, Inc. is serving as the sole book-running manager for the offering. Ellenoff Grossman & Schole LLP is serving as Issuer’s Counsel with Schiff Hardin serving as Underwriter’s Counsel. MaloneBailey, LLP serves as auditor. American Stock Transfer & Trust Company is acting as trustee.